This trial has been completed.

Condition autosomal dominant polycystic kidney disease
Sponsor Kyorin University
Collaborator Otsuka Pharmaceutical Co., Ltd.
Start date January 2014
End date December 2016
Trial size 80 participants
Trial identifier NCT02322385, Kyorin-PKD-1


Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disease. We plan DNA analysis using the next generation sequencer (NGS) and examine the relationship between mutational types and clinical phenotypes. The accuracy of DNA analysis with NGS is tested by Sanger's method. The kidney and life survival curves will be compared between PKD1, PKD2 and non-ADPKD family members.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

The relationship between mutational types and phenotypes
time frame: Depends on the observational period at least more than one year.

Secondary Outcomes

Identify the efficacy of next generation sequencing method
time frame: One year.

Eligibility Criteria

All participants from 20 years up to 80 years old.

Inclusion Criteria: - The unrelated patients with ADPKD. Exclusion Criteria: - The patients whose clinical data are not compiled.

Additional Information

Official title Mutational Types and Phenotypes Relationship in Autosomal Dominant Polycystic Kidney Disease
Description 80 unrelated patients with ADPKD attending to the Kyorin University Hospital whose clinical data are compiled. DNA analysis is performed at Otsuka Pharmaceutical Laboratory. Clinical data include total kidney volume (TKV), TKV slope, eGFR, eGFR slope and other clinically relevant data.
Trial information was received from ClinicalTrials.gov and was last updated in February 2017.
Information provided to ClinicalTrials.gov by Kyorin University.